Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06832839

Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

Status
Recruiting
Phase
Study type
Observational
Enrollment
360 (estimated)
Sponsor
Beijing Tiantan Hospital · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Detailed description

Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.

Conditions

Interventions

TypeNameDescription
PROCEDURERevascularizationRevascularization

Timeline

Start date
2024-12-16
Primary completion
2025-12-31
Completion
2027-12-31
First posted
2025-02-18
Last updated
2025-02-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06832839. Inclusion in this directory is not an endorsement.